Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsPlatelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCIIs platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy AcA pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Assessment of oral antithrombotic therapy by platelet function testing.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?Advances in the monitoring of anti-P2Y12 therapy.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Clinical impact of genetically determined platelet reactivity.Platelet function testing and tailored antiplatelet therapy.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Cytochrome P450 pharmacogenetics in African populations.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.Perioperative management and monitoring of antiplatelet agents: a focused review on aspirin and P2Y12 inhibitorsPre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?Oral antiplatelet therapy: impact for transfusion medicine.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Personalizing antiplatelet therapies: What have we learned from recent trials?The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity.Deuterated clopidogrel analogues as a new generation of antiplatelet agents.Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction.Low On-Treatment Platelet Reactivity Predicts Long-Term Risk of Bleeding After Elective PCI.Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease.The predictive value of multiple electrode platelet aggregometry for postoperative bleeding complications in patients undergoing coronary artery bypass graft surgery.Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry.[Gastrointestinal bleeding in cardiological patients].[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser.[The use of platelet aggregation inhibitors in the perioperative period].Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention.
P2860
Q26775125-F9C4B536-26F8-4A06-83F5-052F5E1DEFFFQ34035039-0D2CB9A0-3F70-4B48-BE3D-659112279691Q34761979-8CDA371C-8710-4755-BD2D-9F0CA50E4774Q35035904-606C4FF8-2BEB-49AB-9952-7775C95676D5Q35985453-021C684C-CD61-40E1-81F5-945FE2C1E68DQ36036395-BFA7B7FF-FEB5-416F-A15C-75B282D8A692Q36081188-680B937C-1451-4491-B783-3EB7F71B4BEFQ37497555-3539475E-919A-4820-AA48-3F8E41AD2BD6Q37841568-AA44BFBE-E380-4EB4-93ED-D08599CA62D6Q37882712-B38B080B-769C-491C-87C6-03A0A26BA97CQ37902507-7BCF9F3E-2F29-497D-B6C2-C183980A6A31Q37923969-5CBC62AF-CF09-49A7-A22C-BCD74AFF54FCQ37973457-5650B9E3-A973-4D2B-8BD4-5872A2BBEF2CQ38037121-7BE964E5-CE61-45D6-8B39-2ABB9E75F8CEQ38053481-52D46A9C-EFC5-4A6E-82D3-3ECB5C34575AQ38059616-FEE98EC2-0D8E-4C8F-B58F-CA1589835A5DQ38094681-D7FEEF58-4728-4B0C-8B68-6FA0D1A6BB6AQ38099235-AF87669D-4010-446B-89C9-5C22DA346D9BQ38099372-6A298891-8CFE-47EE-8866-18D07AF6C7F8Q38132923-2DD6F2A0-5DA7-4F7B-8F88-BAAB45129322Q38444425-85CBF6FE-E1E5-45AD-803C-94A145A83B5CQ38475429-D7D6E04C-8011-42BF-ABC7-B31A53AD4574Q38631422-EBE73B64-38D4-43BA-BC7B-A6B26537047BQ38682012-0834F3F1-75C2-4A4C-8D64-90DD817F561EQ38754884-29FBB804-6481-4C9F-8FA5-E7531361B6AFQ38958862-B217340D-8EF6-455F-ABAF-71DFC3AFA4B4Q39382840-D458CAB5-F3D8-49E0-BBAE-C09BD1201919Q39704629-1C547CE3-FC22-4CE1-A8F8-682106BF94A0Q39781068-88A4F3C7-7331-42D1-A3CF-9C163869BC12Q40257227-81CB914B-9E98-4F8A-874B-38F003349D2DQ40727154-E45F97F0-CFE1-44E7-981E-AC3226D7E4A2Q41069868-5188290C-35E4-45AB-A9A5-61B90260D1A6Q41141258-C77611D8-A9D6-43FF-9904-AF8C1FE69DDAQ41159239-3189761F-D35C-40BF-8841-02484CD0FF47Q43515622-C281B457-8DB1-4086-B29C-E79CB01D8B67Q44466856-24C3C07C-8E26-4EEA-8D0C-06916BD317BBQ44607568-C97C0F5C-58D4-4E48-B957-FD6E7BEC03B6Q44664771-62EFDD3A-84B4-4468-876F-BA024B926B08Q50076960-C91F0F5F-A836-4C22-A897-ACABD4A78937Q50791517-140E8CFE-5462-472A-B716-33B58C7BB0CD
P2860
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Platelet aggregation and its a ...... dence of a therapeutic window.
@en
Platelet aggregation and its a ...... dence of a therapeutic window.
@nl
type
label
Platelet aggregation and its a ...... dence of a therapeutic window.
@en
Platelet aggregation and its a ...... dence of a therapeutic window.
@nl
prefLabel
Platelet aggregation and its a ...... dence of a therapeutic window.
@en
Platelet aggregation and its a ...... dence of a therapeutic window.
@nl
P50
P1476
Platelet aggregation and its a ...... dence of a therapeutic window.
@en
P2093
Dirk Sibbing
P304
P356
10.1016/J.JACC.2010.03.048
P407
P577
2010-07-01T00:00:00Z